Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Carcinoma, Neuroendocrine × Nivolumab × Clear all

Phase

Status

Active not recruiting 4 Unknown 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 79 Carcinoma, Non-Small-Cell Lung 73 Carcinoma, Renal Cell 42 Neoplasms 40 Neoplasm Metastasis 38 Squamous Cell Carcinoma of Head and Neck 33 Carcinoma, Hepatocellular 31 Colorectal Neoplasms 30 Pancreatic Neoplasms 23 Stomach Neoplasms 17 Lung Neoplasms 17 Carcinoma, Transitional Cell 16 Ovarian Neoplasms 14 Head and Neck Neoplasms 14 Hodgkin Disease 13 Breast Neoplasms 13 Small Cell Lung Carcinoma 12 Urinary Bladder Neoplasms 11 Recurrence 11 Prostatic Neoplasms 10 Lymphoma 10 Kidney Neoplasms 10 Brain Neoplasms 10 Advanced Cancer 10 Triple Negative Breast Neoplasms 9 Mesothelioma 8 Leukemia, Myeloid, Acute 8 Glioma 8 Glioblastoma 8 Uveal Melanoma 7

Interventions

Everolimus 7 avelumab 3 Etoposide 3 Cisplatin 3 Bevacizumab 3 azaspirane 2 Temozolomide 2 Irinotecan 2 veliparib 1 tocilizumab 1 selinexor 1 pralsetinib 1 pertuzumab 1 pembrolizumab 1 pasireotide 1 irinotecan sucrosofate 1 gallium Ga 68 dotatate 1 carfilzomib 1 berzosertib 1 belinostat 1 Topotecan 1 TLC 388 1 Radiotherapy 1 Radiosurgery 1 Positron Emission Tomography Computed Tomography 1 Podophyllotoxin 1 Platinum 1 Paclitaxel 1 Octreotide 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03591731 2025-04-01

NIPINEC

Intergroupe Francophone de Cancerologie Thoracique

Phase 2 Completed

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡